Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Calgary

$17,500.00

Functional characterization of Anti- and Pro-tumorigenic Immune Cell States in Glioblastoma

EF 2020-21

Résumé
Glioblastoma is one of the most deadly human cancers, with very few examples of long term survivors. Despite modern sophisticated treatment regimens, including surgery, chemotherapy, and radiotherapy, survival outcomes for glioma patients remains at a dismal 14.6 months. In recent years, immunotherapies, which reprogram the immune system to recognize and target malignant tumors, have made a breakthrough as a curative therapy for many cancers. Yet, these therapies have been unsuccessful in glioblastoma, due to the unique immune repertoire in the brain and a poor understanding of how current treatments affect this environment. In our previous study of the brain tumor microenvironment, we identified the cytokine interleukin 33 (IL33) as a driver of inflammatory gliomas that recruits and reprograms innate immune cells in the brain to promote rapid and ultimately fatal tumor growth. Furthermore, we found that by crippling the ability of IL33 to enter the nucleus of glioma cells, tumors were no longer capable of developing in mice. We therefore hypothesize that the immune system in brain tumors can be in pro- or anti-tumorigenic states, and an understanding of how to exploit these states will be key in the development of effective immunotherapeutic drugs to treat glioma. To this end, our proposal has two major aims: (i) to understand how current standard-of-care therapies program innate immune cells and (ii) to ascertain the underlying regulation of pro- and anti- tumorigenic environments that promote and suppress tumor progression. With this information, clinical practice for current therapeutics can be modified to maximize the efficacy of immunotherapies and future studies will have immunotherapeutic targets to validate for clinical application.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
449700
Name
Menon Shyam V
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Functional characterization of Anti- and Pro-tumorigenic Immune Cell States in Glioblastoma
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Brain Tumor; Dexamethasone; Glioblastoma; Immunotherapy; Innate Immune Reprogramming; Microglia; Standard Of Care Therapy; Tumor Microenvironment
Abstract
Glioblastoma is one of the most deadly human cancers, with very few examples of long term survivors. Despite modern sophisticated treatment regimens, including surgery, chemotherapy, and radiotherapy, survival outcomes for glioma patients remains at a dismal 14.6 months. In recent years, immunotherapies, which reprogram the immune system to recognize and target malignant tumors, have made a breakthrough as a curative therapy for many cancers. Yet, these therapies have been unsuccessful in glioblastoma, due to the unique immune repertoire in the brain and a poor understanding of how current treatments affect this environment. In our previous study of the brain tumor microenvironment, we identified the cytokine interleukin 33 (IL33) as a driver of inflammatory gliomas that recruits and reprograms innate immune cells in the brain to promote rapid and ultimately fatal tumor growth. Furthermore, we found that by crippling the ability of IL33 to enter the nucleus of glioma cells, tumors were no longer capable of developing in mice. We therefore hypothesize that the immune system in brain tumors can be in pro- or anti-tumorigenic states, and an understanding of how to exploit these states will be key in the development of effective immunotherapeutic drugs to treat glioma. To this end, our proposal has two major aims: (i) to understand how current standard-of-care therapies program innate immune cells and (ii) to ascertain the underlying regulation of pro- and anti- tumorigenic environments that promote and suppress tumor progression. With this information, clinical practice for current therapeutics can be modified to maximize the efficacy of immunotherapies and future studies will have immunotherapeutic targets to validate for clinical application.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Menon, Shyam V
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~